Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of C$14.82 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares trading hands.
Oncolytics Biotech Stock Performance
The company has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The business’s fifty day moving average is C$14.90 and its 200-day moving average is C$14.91.
Insider Buying and Selling
In related news, Director Bernd Robert Seizinger purchased 60,000 shares of Oncolytics Biotech stock in a transaction on Wednesday, February 11th. The stock was acquired at an average price of C$1.14 per share, for a total transaction of C$68,400.00. Following the completion of the transaction, the director directly owned 526,991 shares in the company, valued at C$600,769.74. This represents a 12.85% increase in their position. Also, insider Andrew P. Aromando acquired 29,600 shares of the stock in a transaction dated Wednesday, February 11th. The shares were bought at an average cost of C$1.18 per share, for a total transaction of C$34,928.00. Following the completion of the transaction, the insider owned 55,100 shares in the company, valued at approximately C$65,018. This represents a 116.08% increase in their ownership of the stock. Insiders purchased 289,232 shares of company stock worth $335,760 in the last quarter. Company insiders own 3.82% of the company’s stock.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Further Reading
- Five stocks we like better than Oncolytics Biotech
- Gilder: Don’t Buy AI Stocks, Do This Instead
- “This AI Giant is About to Go Bust”
- The gold chart Wall Street is terrified of…
- Warning: You are not moving fast enough
- What central banks are doing with gold right now
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
